Iberdomide

FPFT-2216 and pomalidomide were synthesized by Fujimoto Pharmaceutical Group. Avadomide, iberdomide, siremadlin, idasanutlin, navtemadlin, milademetan, and MG-132 were procured from MedChemExpress; Z-VRPR-FMK and phorbol 12-myristate 13-acetate (PMA) were procured from Adipogen Life Sciences. Lenalidomide and ionomycin were obtained from Cayman Chemical, BAY 11-7082 from FUJIFILM Wako Pure Chemical Corporation, and safimaltib from Selleck Chemicals. Rituxan Intravenous Infusion (rituximab) was obtained from Zenyaku Kogyo. Z-VRPR-FMK was dissolved in PBS, and other reagents were dissolved in DMSO. The final DMSO concentration used for in vitro experiments did not exceed 0.25%.

The following chemicals and reagents were used: EZT, iberdomide, MK571 (MedChemExpress, Monmouth Junction, NJ, USA), BCT (Adooq Bioscience, Irvine, CA, USA), PAX, nutlin-3a (Cayman Chemical, Ann Arbor, MI, USA), NS1619, ceefourin 1 (Abcam, Cambridge, UK), docetaxel (DTX) (TCI, Tokyo, Japan), PTX, DOX hydrochloride, CIS, RPMI 1640 medium (FUJIFILM, Osaka, Japan), DiBAC₄(3), WST-1 (Dojindo, Kumamoto, Japan), Select Pre-designed/Validated siRNAs as a negative control (Pre-designed, No. 1), CRBN (Pre-designed, ID#: s534902), FBXW7 (Pre-designed, ID#: s224356), MDM2 (Validated, ID#: s8630) and Lipofectamine^® RNAiMAX (Thermo Fisher Scientific, Waltham, MA, USA), and ReverTra Ace (ToYoBo, Osaka, Japan). The other chemicals used in the present study were from Sigma-Aldrich (St. Louis, MO, USA), FUJIFILM, and Nacalai Tesque (Kyoto, Japan), unless otherwise stated.